FDA Orange Book · active-ingredient family
Gallium ga-68 edotreotide
Gallium ga-68 edotreotide is approved as 1 brand and 1 generic application in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:GALLIUM GA 68 EDOTREOTIDE · NDA 210828
1
Brand (NDA)
1
Generics (ANDA)
0
Listed patents
2
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| GALLIUM GA 68 EDOTREOTIDERLD | UIHC PET IMAGING | NDA 210828 | AP | Aug 21, 2019 |
Generic (ANDA) products (1)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| GALLIUM GA 68 EDOTREOTIDE | METHODIST | ANDA 218845 | AP | Oct 10, 2025 |
Marketing exclusivity (2)
- ODE-383Orphan-drug exclusivity (7 years)
Aug 21, 2026
in 2 mo
- WExclusivity withdrawal / change
Aug 21, 2026
in 2 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Gallium ga-68 edotreotide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

